Synaptogenix, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2021. The supplied filing is for Synaptogenix, Inc. (Nasdaq: SNPX), not TAO Synergies Inc. Synaptogenix is a clinical-stage biopharmaceutical company focused primarily on bryostatin-1 for Alzheimer’s disease (AD). It became independent in December 2020; 2020 comparative figures include periods when its business was part of its former parent.
Financial results and liquidity
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | $0 in 2021 and 2020 | $0 in 2021 and 2020 |
| Research and development | $986,280 in 2021; $600,065 in 2020 | $2,138,060 in 2021; $993,310 in 2020 |
| General and administrative | $1,308,893 in 2021; $2,407,702 in 2020 | $3,312,306 in 2021; $4,622,668 in 2020 |
| Net loss | $2,293,842 in 2021; $2,932,126 in 2020 | $5,448,219 in 2021; $5,469,470 in 2020 |
| Loss per share, basic and diluted | $0.58 in 2021; $2.33 in 2020 | $1.53 in 2021; $4.35 in 2020 |
| Net cash used in operating activities | $5,585,322 for the six months in 2021; $3,645,433 in 2020 |
At June 30, 2021, cash and cash equivalents were $31.7 million, total current assets $32.9 million, current liabilities $770,000, and working capital $32.2 million. Total liabilities were current liabilities only; the filing reports no debt balance. Cash rose from $5.8 million at December 31, 2020, mainly following equity offerings and warrant exercises. Financing cash inflows were $31.5 million for the first half of 2021. The company reported no income tax provision. Profitability margins are not meaningful because the company had no revenue and incurred operating losses.
Changes versus the comparable period
- For the first half, R&D expense increased about 115%, reflecting the ongoing AD Phase 2 trial; G&A expense decreased about 28%, principally because 2020 included one-time strategic transaction, restructuring, and spin-off costs and higher former-CEO-related costs.
- Six-month net loss was nearly unchanged year over year. Second-quarter net loss decreased about 22%, as lower G&A more than offset higher R&D.
- Operating cash use increased by about $1.9 million year over year, reflecting working-capital movements and higher cash trial spending.
- Common shares outstanding increased from 1,257,579 at year-end 2020 to 6,038,798 at June 30, 2021. The company completed January and June private placements and received approximately $7.6 million from warrant exercises during the first half. A 1-for-4 reverse stock split in May is reflected retrospectively in the reported share data.
Outlook, commentary, risks, and unusual items
- Management expected cash available at the filing date—approximately $32.1 million, including about $1.3 million received in July and early August—to fund projected operations for at least 12 months from the filing date. The company expects continuing losses and says additional capital may be needed for further development; future equity financing could dilute shareholders, while debt or licensing arrangements may impose restrictive terms or require surrendering rights.
- The active AD Phase 2 trial was designed for approximately 100 participants. The filing estimates total trial costs at approximately $9.6 million, with a $2.7 million NIH grant reducing the estimated company-funded cost. It reports about $4.0 million of cumulative trial expense in the notes, while MD&A cites approximately $4.6 million of cumulative WCT-related services and pass-through expenses; investors should reconcile these descriptions.
- A prior confirmatory Phase 2 trial did not meet its primary endpoint, and the treatment-placebo difference in the reported post-hoc moderate-stratum analysis was not statistically significant. Management described a possible benefit signal but acknowledged the limitations; the filing provides no new efficacy results for the ongoing trial.
- Development risks include clinical-trial outcomes and timing, FDA approval, access to bryostatin supply, competition, and potential COVID-19 disruption to enrollment and trial operations. Existing NCI supply arrangements may not cover all trials needed, and alternative supply arrangements may be necessary.
- The company disclosed potential uncapped reciprocal indemnification obligations under its separation and tax agreements, including possible tax exposure if the spin-off is determined taxable; no indemnification claims were reported as of the filing. It also disclosed a full valuation allowance against deferred tax assets and possible limits on use of tax-loss carryforwards.
- Disclosure controls and procedures were reported as ineffective due to weaknesses in segregation of duties, period-end financial reporting and documentation, and IT general controls. Management nevertheless stated that the financial statements fairly present the company’s condition and results in all material respects.
- Subsequent items included an August memorandum of understanding with Nemours for a proposed Fragile X trial, with estimated trial and IND costs of about $700,000, and approximately $800,000 of additional warrant exercise proceeds through August 10.
Key facts for investors to verify
- Confirm the registrant identity: this filing is Synaptogenix, Inc., rather than TAO Synergies Inc.
- Review the ongoing Phase 2 AD trial’s enrollment, spending, NIH reimbursements, timelines, and any efficacy updates; reconcile the filing’s differing cumulative trial-cost figures.
- Assess cash runway against the company’s expected clinical spending and the stated need for possible additional financing.
- Evaluate dilution from outstanding warrants, options, and equity awards; reported outstanding warrants totaled approximately 6.9 million at June 30, 2021.
- Monitor bryostatin supply availability, COVID-related trial disruption, spin-off tax and indemnification exposure, and remediation of the disclosed control weaknesses.